Clinical trials
Moderately to Severely Active Ulcerative Colitis clinical trials
Below are recruiting moderately to severely active ulcerative colitis clinical trials, each written for real people, not researchers. We’re tracking 101 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07333716RecruitingPhase 2
Desloratadine for mild to moderate UC
This trial tests whether desloratadine, an allergy medicine (antihistamine), can help reduce inflammation in people with mild to moderate ulcerative colitis. All participants must already be taking mesalamine and cannot be on other stronger UC treatments.
Shibīn al Kawm, MenofiaAges 18–65 - NCT06595719Recruiting
Probiotics plus standard care for mild to moderate UC
This trial tests whether adding a multi-strain probiotic supplement to your usual care can help manage mild to moderate ulcerative colitis (UC). It lasts 12 weeks and requires you to stay on your current medications without changes.
Cheras, Kuala LumpurAges 18–90 - NCT07302360Recruiting
Guselkumab for ulcerative colitis in Chinese patients
This study tracks how well guselkumab (Tremfya) works in real-world Chinese patients with moderate to severe ulcerative colitis who haven't tried advanced therapies before. It helps doctors understand how the drug performs outside of controlled trials.
BeijingAges 18 years+ - NCT07298421RecruitingPhase 3
Testing afimkibart for children with Crohn's disease
This trial tests a medicine called afimkibart for children with moderately to severely active Crohn's disease. It aims to see how well the drug works and how safe it is when used for both starting and ongoing treatment.
New York, New YorkAges 2–17 - NCT07296315RecruitingPhase 2
Testing a new treatment for mild-to-moderate ulcerative colitis
This study tests an investigational drug for people with active mild-to-moderate ulcerative colitis. It aims to see if the drug can improve symptoms without needing advanced treatments like biologics.
Miami, FloridaAges 16 years+ - NCT07265570RecruitingPhase 2
ISM5411 for active ulcerative colitis
This trial tests an experimental drug (ISM5411) for people with active ulcerative colitis. The goal is to see if the drug can reduce inflammation and improve symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT07258771RecruitingPhase 4
Upadacitinib plus steroids vs steroids alone for severe ulcerative colitis
This trial tests if adding upadacitinib (a pill) to standard steroid treatment helps people with a severe flare of ulcerative colitis feel better faster. You may qualify if you are having frequent bloody stools and signs of serious inflammation, and you haven't tried upadacitinib before.
Ann Arbor, MichiganAges 18–75 - NCT07235904RecruitingPhase 4
Mirikizumab vs standard treatment for newly diagnosed ulcerative colitis
This trial tests if starting with the stronger drug mirikizumab (top-down therapy) works better than the usual treatment with azathioprine for people newly diagnosed with moderate-to-severe ulcerative colitis. It aims to see which approach controls inflammation and improves symptoms faster.
KielAges 18–75 - NCT06895252Recruiting
Fecal transplant and diet for new ulcerative colitis
This study tests whether a combination of fecal transplant (transferring healthy stool into your gut) and dietary changes can help control inflammation in people recently diagnosed with active ulcerative colitis. It may offer a new treatment option before starting stronger medications.
Kochi, KeralaAges 18–75 - NCT07229950RecruitingPhase 2
Experimental tablet for moderate to severe Ulcerative Colitis
This trial tests an experimental tablet, HRS-7085, for people with moderate to severe Ulcerative Colitis who haven't gotten enough help from standard treatments. The goal is to see if the drug can reduce inflammation and improve symptoms.
Chengdu, SichuanAges 18–75 - NCT07196748RecruitingPhase 3
Icotrokinra for adults and teens with moderate to severe ulcerative colitis
This trial tests a new oral medication, icotrokinra, for people with moderately to severely active ulcerative colitis. It may be an option if you have not responded well enough to standard treatments or newer advanced therapies.
Chandler, ArizonaAges 12 years+ - NCT07186101RecruitingPhase 2
Testing a new combo therapy for ulcerative colitis
This study tests two drugs together (LY4268989 and mirikizumab) in people with moderate to severe ulcerative colitis. It's for those whose current treatments didn't work well enough.
Scottsdale, ArizonaAges 18–80 - NCT07184996RecruitingPhase 3
Study of duvakitug for moderate to severe ulcerative colitis
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
Peoria, ArizonaAges 16–80 - NCT07158242RecruitingPhase 3
Study of a Medication for Children with Active Ulcerative Colitis
This study is testing an investigational medication for children with ulcerative colitis that has not responded well to standard treatments. It aims to see if the drug is safe and effective in reducing symptoms.
Aurora, ColoradoAges 2–17 - NCT05456893Recruiting
Testing blood and stool markers in active ulcerative colitis treatments
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
Nancy, LorraineAges 18 years+ - NCT07136116Recruiting
Study of risankizumab for moderate to severe ulcerative colitis in Japan
This study looks at how well risankizumab (an injected medicine) works for people with moderate to severe ulcerative colitis. It tracks your symptoms using a mobile app to see if the drug helps control the disease.
Nagakute, Aichi-kenAges 15 years+ - NCT07115862Recruiting
Pomegranate juice study for mild to moderate ulcerative colitis
This trial tests if drinking pomegranate juice can help people with mild to moderate ulcerative colitis. You may be eligible if your diet is low in fruits and vegetables and you are on stable medications.
Los Angeles, CaliforniaAges 18 years+ - NCT07111572Recruiting
Can gut markers show early if a UC treatment works?
This study looks at stool samples to see if certain markers can quickly tell whether a biologic medicine is starting to work for moderate-to-severe ulcerative colitis. If successful, this could help doctors make faster, smarter treatment decisions.
Jinan, ShandongAges 18–75 - NCT06453317RecruitingPhase 2
Comparing UC treatments: infliximab vs ustekinumab vs both
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
LodzAges 18–64 - NCT07083193RecruitingPhase 1/Phase 2
Study of AC-101 tablets for moderate to severe ulcerative colitis
This trial tests a new tablet called AC-101 for people with active moderate to severe ulcerative colitis. It aims to see if the drug can reduce symptoms like diarrhea and bleeding and help the gut heal.
Guangzhou, GuangdongAges 18–75 - NCT07080034RecruitingPhase 2
Testing BCD-261 for moderate to severe ulcerative colitis
This trial tests a new drug called BCD-261 for people with moderate to severe ulcerative colitis that hasn't gotten better with standard treatments. It aims to see if the drug can improve symptoms and how safe it is.
Barnaul, Altayskiy KrayAges 18–75 - NCT07012395RecruitingPhase 2
Long-acting antibodies for moderate to severe ulcerative colitis
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
Canoga Park, CaliforniaAges 18–75 - NCT06979336RecruitingPhase 2
New drug for moderate to severe UC
This study tests an experimental drug called RO7837195 for people with moderate to severe ulcerative colitis (UC) who haven't gotten enough help from other treatments. It aims to see if this new drug can reduce inflammation and improve symptoms.
Lancaster, CaliforniaAges 18 years+ - NCT06937086RecruitingPhase 3
Mirikizumab plus tirzepatide for UC with obesity
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
Dothan, AlabamaAges 18–70
Hear when a new Moderately to Severely Active Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for moderately to severely active ulcerative colitis?
- Yes. Clin2 currently lists 101 recruiting moderately to severely active ulcerative colitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a moderately to severely active ulcerative colitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a moderately to severely active ulcerative colitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.